https://orcid.org/0000-0001-7311-8171
References
- Yoo J-W, Irvine DJ, Discher DE, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10(7):147–535.
- Li Z, Tan S, Li S, et al. Cancer drug delivery in the nano era: an overview and perspectives (Review). Oncol Rep. 2017;38(2):611–624.
- Gujrati V, Lee M, Ko YJ, et al. Bioengineered yeast-derived vacuoles with enhanced tissue-penetrating ability for targeted cancer therapy. Proc Natl Acad Sci USA. 2016;113(3):710–715.
- Armstrong J. Yeast vacuoles: more than a model lysosome. Trends Cell Biol. 2010;20(10):580–585.
- Kim BN, Ahn JY, Song MS, et al. Development of odorous gases reduction agents using recombinant Yeast-Derived extract. Toxicol Environ Health Sci. 2019;11(4):271–277.
- Flannery AR, Graham LA, Stevens TH. Topological characterization of the c, c', and c" subunits of the vacuolar ATPase from the yeast Saccharomyces cerevisiae. J Biol Chem. 2004;279(38):39856–39862.
- Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1–14.
- Li K, Lv XX, Hua F, et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Int J Cancer. 2014;134(3):692–702.
- Chen GY, Brown NK, Wu W, et al. Broad and direct interaction between TLR and siglec families of pattern recognition receptors and its regulation by Neu1. Elife. 2014;3:e04066.
- Rybka J, Butrym A, Wróbel T, et al. The expression of toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy. Leuk Res. 2015;39(3):318–322.
- Gilad Y, Firer M, Gellerman G. Recent innovations in peptide based targeted drug delivery to cancer cells. Biomedicines. 2016;4(2):11.
- Paul C, Liliemark J, Tidefelt U, et al. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit. 1989;11(2):140–148.
- Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–782.
- Ståhl S, Gräslund T, Karlström AE, et al. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35(8):691–712.
- Ghasemi M, Okay M, Turk S, et al. The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia. J Renin Angiotensin Aldosterone Syst. 2019;20(2):1470320319851310.
- Yoon J, Sekhon SS, Kim YH, et al. Enhanced lysosomal activity by overexpressed aminopeptidase Y in Saccharomyces cerevisiae. Mol Cell Biochem. 2016;417(1-2):181–189.
- Giraldo AMV, Appelqvist H, Ederth T, et al. Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death. Biochem Soc Trans. 2014;42(5):1460–1464.
- Choi W, Heo MY, Kim SY, et al. Encapsulation of daunorubicin into saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment. J Biotechnol. 2020;308:118–123.
- Gong Y, Duvvuri M, Krise JP. Separate roles for the golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem. 2003;278(50):50234–50239.